Loading...
•
Jun 30, 2024
scPharmaceuticals Q2 2024 Earnings Report
scPharmaceuticals' Q2 2024 financial results were announced, featuring FUROSCIX revenue growth and progress in life cycle management.
Key Takeaways
scPharmaceuticals reported Q2 2024 net FUROSCIX revenue of $8.1 million, a 33% increase sequentially, with approximately 9,300 FUROSCIX doses filled. The company completed financing to extend cash runway through expected profitability and advanced FUROSCIX growth initiatives, including label expansion and sNDA submissions.
Net FUROSCIX revenue reached $8.1 million, up 33% sequentially from Q1 2024.
Approximately 9,300 FUROSCIX doses were filled, a 15% sequential increase from Q1 2024.
FDA approval was received to expand the FUROSCIX indication to include patients with NYHA Class IV chronic heart failure.
Positive topline PK/PD data was announced for the FUROSCIX autoinjector, with an sNDA submission targeted by the end of the year.
scPharmaceuticals
scPharmaceuticals
scPharmaceuticals Revenue by Segment
Revenue by Segment
FUROSCIX Revenue
CapyFin.com Forward Guidance
scPharmaceuticals anticipates continued growth and progress with FUROSCIX, supported by recent FDA approvals, positive clinical data, and transformational financing, extending the cash runway through profitability.
Positive Outlook
- FDA approval to expand FUROSCIX indication to include NYHA Class IV heart failure patients.
- Positive PK/PD data from a study of the low volume autoinjector, with sNDA submission targeted by the end of the year.
- FDA acceptance of sNDA seeking to expand FUROSCIX label into chronic kidney disease.
- Completed transformational financing with healthcare-focused institutional investors.
- Financing extends cash runway through profitability.
Challenges Ahead
- Dependence on the commercial success of FUROSCIX and other product candidates.
- Risks related to receipt of regulatory approval for product candidates.
- Risks related to the ability to manufacture sufficient product for commercialization.
- History of operating losses and expectation to incur significant and increasing losses.
- The terms of our credit facility place restrictions on our operating and financial flexibility